Amylyx Pharmaceuticals, Inc. Cash and Restricted Cash
Amylyx Pharmaceuticals, Inc. (AMLX) had Cash and Restricted Cash of $50.31 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $50.31M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $230.12M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $227.64M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $226.16M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $50.31M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $230.12M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $227.64M 10-K · filed 2026-03-03 |
| 2025-09-30 | $226.16M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $59.54M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $61.21M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $78.84M 10-K · filed 2026-03-03 |
| 2024-09-30 | $73.28M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $75.72M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $171.27M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $170.92M 10-K · filed 2025-03-04 |
| 2023-09-30 | $135.98M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |